Rekombinant İnsan İnsülini Üretimi

Biyoteknoloji ve ilaç üretiminin buluşması

Pharmaceutical & Drug Manufacturing Global Industrial Scale $35 billion

Genel Bakış

Recombinant human insulin is produced using genetically engineered Escherichia coli or Saccharomyces cerevisiae that express the human insulin gene. This biotechnological process replaced the previous method of extracting insulin from pig and cow pancreases, providing unlimited supply with reduced immunogenicity. The process involves fermentation, cell lysis, inclusion body solubilization, refolding, enzymatic modification, and multi-step chromatographic purification to produce pharmaceutical-grade insulin.

Kimyasal Süreç

E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by reversed-phase and ion-exchange chromatography.

Proinsulin →[Trypsin + Carboxypeptidase B] Insulin (A-chain + B-chain linked by disulfide bonds) + C-peptide

Hammaddeler

  • Glucose (C₆H₁₂O₆) — Corn processing (Carbon source for fermentation)
  • Ammonium sulfate ((NH₄)₂SO₄) — Chemical synthesis (Nitrogen source)
  • Trypsin (enzyme) — Recombinant production (C-peptide cleavage)

Son Ürünler

  • Recombinant human insulin — Diabetes treatment (>98% purity, multiple analog forms)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annually.

Güvenlik Hususları

Son İnovasyonlar

Insulin analogs (lispro, glargine, aspart) with modified amino acid sequences provide faster or longer-acting profiles.
Cell-free protein synthesis and oral insulin delivery systems are in advanced development stages.

Daha fazlası Pharmaceutical & Drug Manufacturing

Amoksisilin Yarı-Sentetik Üretimi

Global Industrial Scale

Fermantasyonla Penisilin G Üretimi

Global Industrial Scale

İbuprofen Sentezi — BHC Yeşil Süreci

Global Industrial Scale

Metformin Hidroklorür Sentezi

Global Industrial Scale

Parasetamol (Asetaminofen) Sentezi

Global Industrial Scale

Proton Pompası İnhibitörleri için Omeprazol Sentezi

Global Industrial Scale

Salisilik Asidin Asetilasyonuyla Aspirin Sentezi

Global Industrial Scale

Frequently Asked Questions

What industry uses Rekombinant İnsan İnsülini Üretimi?
Rekombinant İnsan İnsülini Üretimi is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in Rekombinant İnsan İnsülini Üretimi?
E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by rev
What is the economic significance of Rekombinant İnsan İnsülini Üretimi?
Rekombinant İnsan İnsülini Üretimi has a market value of $35 billion.
What is the environmental impact of Rekombinant İnsan İnsülini Üretimi?
Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annua
What raw materials are used in Rekombinant İnsan İnsülini Üretimi?
The main raw materials include: Glucose (C₆H₁₂O₆), Ammonium sulfate ((NH₄)₂SO₄), Trypsin (enzyme).